Back to search
GERD - PPI Responders
Clinical trial pipeline · Data from ClinicalTrials.gov
See which GERD - PPI Responders trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which GERD - PPI Responders trials you may qualify forThis study will be conducted as a multi-center, randomized, double-blind, placebo-controlled trial to evaluate the effect of MHS-1031 on heartburn-free days in…
Gastroesophageal reflux disease (GERD) is a very common condition affecting up to 30% of adults. To date, therapy consists of powerful acid suppression with pro…
The prevalence of GERD is estimated to be as high as 20% in the US, and up to 50% remain symptomatic on proton pump inhibitor (PPI) therapy. The clinical approa…